Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

Autor:	Harlay V; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France; Vincent.harlay@ap-hm.fr., Bertucci A; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France.; Institut de Neurophysiopathologie, Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées or Institut National Polytechnique (INP), Marseille, France., Boucard C; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France.; Plateforme PE'TRANSLA', Aix-Marseille University, Réseau Préclinique et Translationnel de Recherche en Neuro-oncologie, Marseille, France., Petrirena G; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France., Campello C; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France., Barrié M; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France., Autran D; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France., Chinot O; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France.; Institut de Neurophysiopathologie, Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées or Institut National Polytechnique (INP), Marseille, France., Tabouret E; Service de Neuro-oncologie, Centre Hospitalier Universitaire Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France.; Institut de Neurophysiopathologie, Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées or Institut National Polytechnique (INP), Marseille, France.; Plateforme PE'TRANSLA', Aix-Marseille University, Réseau Préclinique et Translationnel de Recherche en Neuro-oncologie, Marseille, France.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2024 Oct; Vol. 44 (10), pp. 4427-4433.
DOI:	10.21873/anticanres.17272
Abstrakt:	Background/aim: Treatment of primary central nervous system lymphoma (PCNSL) includes high dose methotrexate-based polychemotherapy (HD-MTX). This study aimed to identify early predictive factors of methotrexate (MTX) delayed elimination. Patients and Methods: We prospectively included all patients with newly-diagnosed PCNSL. Daily serum and urinary creatinine and ionogram were collected. We generated two independent cohorts: a training cohort (TC) and a confirmatory cohort (CC). Results: We included for analysis 64 cures of HD-MTX (20 patients) in the TC and 59 cures (22 patients) in the CC. Median elimination time of MTX was 95 h and 96 h in the TC and CC, respectively. In multivariate analysis, older age (p=0.004), low Karnofsky Performance Status (p=0.036) and high urinary K + (p=0.001) were associated with delayed MTX elimination. An optimal cutoff for urinary K + was defined. In the CC, we confirmed that high urinary K + (p=0.004) remained associated with delayed MTX elimination. Conclusion: High urinary K + may be predictive of delayed MTX elimination in primary central nervous system lymphoma. Its relevance as a decision-making factor needs to be validated in additional prospective studies. (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu